Lassa fever vaccine trial begins in Maryland

nih.gov

A clinical trial for a Lassa fever vaccine has started at the University of Maryland School of Medicine. This NIH-sponsored trial aims to test the safety and immune response of a candidate vaccine called LASSARAB in healthy adults. The trial will enroll up to 55 participants aged 18 to 50. They will receive two doses of the vaccine or a rabies vaccine as a control, spaced 28 days apart. LASSARAB is based on a modified rabies vaccine and has shown promise in nonhuman primates. If successful, it could help prevent both Lassa fever and rabies, pending further testing and FDA approval.


With a significance score of 3.2, this news ranks in the top 18% of today's 18126 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 9000 minimalists.


loading...

Timeline:

    [2.7]
    Lassa fever vaccine study begins enrollment in Maryland (contagionlive.com)
    5h
    Source